Ann: Commencement of Legal Proceedings Against BARD1, page-87

Luvit, Morgenlofting and Whytee sound the most informed on this subject, even if they see it from different sides of the fence. I recall something from the recent Eureka interview about the work being transferred from where DR IF is based in Europe, back to Australia. Not sure if that’s a part of the dispute.

Possibly the merger, Covid, best use of capital, revised priorities and personalities all played a part in the work toward the milestones not being progressed in a manner that fits within the originally envisaged timeline.

I’d be quite happy for them to get the Performance Options if the milestones were achieved. With the BD1 share price now higher, why not raise the necessary Capital and progress this test as well as the others. As the MD said in the interview ‘we have multiple shots on goal’.
If they can all still work together then you’d think a deal could be done – rather than lawyers at ten paces. Maybe the best outcome would be to extend the date for the milestones to be achieved, give them a few more performance shares as compensation, raise the Capital and see if the test can achieve the milestones.